|
Find information on thousands of medical conditions and prescription drugs.
|
|
|
Loestrin
Oral contraceptives come in a variety of formulations. The main division is between combined oral contraceptive pills, containing both estrogen and progesterone, and progesterone only pills (mini-pills). Combined oral contraceptive pills also come in varying types, including varying doses of estrogen, and whether the dose of estrogen or progesterone changes from week to week. more...
Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Combined oral contraceptive pills
All contain the estrogen ethinyl estradiol, although in varying amounts, and one of a number of different progesterones. They are taken for 21 days with then a 7 day gap during which a withdrawal bleed (often, but incorrectly, referred to as a menstrual period) occurs. These differ in the amount of estrogen given, and whether they are monophasic (only one dose of estrogen and progesterone during the 21 days) or multiphasic (varying doses).
Monophasic
These are given as 21 tablets of estrogen and progesterone, followed by 7 tablets of placebo. Different formulations contain different amounts of estrogen and progesterone:
- 20 mcg estrogen
- 0.1 mg levonorgestrel (Alesse®, Levline®)
- 1 mg norethindrone acetate (Loestrin 1/20®Fe)
- 30 mcg estrogen
- 0.15 mg levonorgestrel (Levlen®, Levora®, Nordette®)
- 0.3 mg norgestrel (Lo-Ovral®)
- 0.15 mg desogestrel (Desogen®, Organon; Ortho-Cept®, Ortho-McNeil)
- 1.5 mg norethindrone acetate (Loestrin® 1.5/30)
- 3.0 mg drospirenone (Yasmin®)
- 35 mcg estrogen
- 0.25 mg norgestimate (Ortho-Cyclen®)
- 0.4 mg norethindrone (Ovcon-35®, Warner Chilcott)
- 0.5 mg norethindrone (Modicon®, Brevicon®)
- 1 mg norethindrone (Ortho-Novum 1/35®, Necon®, Norethin®, Norinyl 1/35®)
- 1 mg ethynodiol diacetate (Demulen 1/35®, Zovia 1/35E®)
- 50 mcg estrogen
- 0.4 mg norethindrone (Ovcon-50®, Warner Chilcott))
- 1 mg norethindrone (Necon 1/50®, Norinyl 1/50®, Ortho-Novum 1/50®, Ovcon-50®)
- 0.5 mg norgestrel (Ovral®)
- 1 mg ethynodiol diacetate (Demulen 1/50®, Zovia 1/50E®)
Multiphasic
- Desogestrel 0.15 mg and ethinyl estradiol 0.02 mg x 14 tablets, followed by ethynil estradiol 0.01 mg x 2 tablets, followed by 5 tablets of placebo (Kariva®, Barr Laboratories; Mircette®, Organon)
- Desogestrel 0.1 mg ethynil estradiol 0.025 mg x 7 tablets, followed by desogestrel 0.125 mg and ethynil estradiol 0.025 mg x 7 tablets, followed by desogestrel 0.15 mg and ethynil estradiol 0.025 mg x 7 tablets, followed by 7 tablets of ferric oxide (Cyclessa®, Organon; Velivet®, Barr Laboratories)
- Norethindrone 0.5 mg and ethinyl estradiol 0.035 mg x 7 tablets, followed by 0.75 mg of norethindrone and 0.035 mg of ethinyl estradiol x 7 tablets, followed by 1 mg of norethindrone and 0.035 of ethinyl estradiol, followed by 7 tablets of placebo (Ortho-Novum 7/7/7®)
- Norethindrone 0.5 mg and 0.035 mg of ethinyl estradiol x 10 tablets, followed by 1 mg norethindrone and 0.035 ethinyl estradiol x 11 tablets, followed by 7 tablets of placebo (Ortho-Novum 10/11®)
Read more at Wikipedia.org
• [List your site here Free!]
|
|
|
|
Contraceptive rights - Policy & Practice
From OB/GYN News,
10/15/03
by Mary Ellen Schneider
Barr Laboratories Inc. will soon hold the exclusive rights to Loestrin (norethindrone acetate and ethinyl estradiol) and Loestrin FE (norethindrone acetate and ethinyl estradiol/ferrous fumarate) oral contraceptive products in the United States and Canada, thanks to a proposed agreement signed by Barr and the Northern Ireland-based Galen Holdings PLC. The agreement also would settle litigation between the two companies over Galen's femhrt hormone therapy and Estrostep oral contraceptives (both containing norethindrone acetate and ethinyl estradiol). The resolution of the litigation would allow Barr to speed up the availability of a generic version of those products, launching its generic drug 6 months before the Galen patent expires. The two companies expect to finalize the agreement at the end of the year. "This is a good deal for both companies," says Galen's chief executive office Roger Boissonneault.
COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2003 Gale Group
Return to Loestrin
|
|